FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47 | -53.5% | 22,348 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $101 | -25.7% | 21,303 | -11.0% | 0.00% | 0.0% |
| Q1 2023 | $136 | -42.9% | 23,947 | +1.5% | 0.00% | -50.0% |
| Q4 2022 | $238 | -100.0% | 23,583 | -6.8% | 0.00% | -50.0% |
| Q3 2022 | $567,000 | +87.1% | 25,293 | +107.1% | 0.00% | +100.0% |
| Q2 2022 | $303,000 | -50.4% | 12,214 | -22.6% | 0.00% | -33.3% |
| Q1 2022 | $611,000 | -29.0% | 15,771 | +7.3% | 0.00% | -25.0% |
| Q4 2021 | $860,000 | +21.8% | 14,696 | +23.4% | 0.00% | 0.0% |
| Q3 2021 | $706,000 | -8.8% | 11,913 | +33.6% | 0.00% | 0.0% |
| Q2 2021 | $774,000 | +24.2% | 8,918 | +18.1% | 0.00% | +33.3% |
| Q1 2021 | $623,000 | +11.6% | 7,552 | +23.0% | 0.00% | 0.0% |
| Q4 2020 | $558,000 | – | 6,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |